DelveInsight’s, “Pulmonary Sarcoidosis Pipeline Insight 2024” report provides comprehensive insights about 10+ companies and 10+ pipeline drugs in Pulmonary Sarcoidosis pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

 

Discover the latest drugs and treatment options in the Pulmonary Sarcoidosis Pipeline. Dive into DelveInsight’s comprehensive report today! @ Pulmonary Sarcoidosis Pipeline Outlook

 

Key Takeaways from the Pulmonary Sarcoidosis Pipeline Report

• In October 2024:- Kinevant Sciences GmbH- A Randomized, Double-blind, Placebo-Controlled Phase 2 Study With Open-label Extension to Assess the Efficacy and Safety of Namilumab in Subjects With Chronic Pulmonary Sarcoidosis. Participants will be randomized to receive namilumab or placebo in the 26-week Double-blind Treatment Period of the study. Namilumab, or placebo, will be administered subcutaneously (SC) every 4 weeks through Week 22 after the initial dosing period.
• In September 2024:- Xentria Inc.- A Seamless, Phase 1b/2 Multiple Ascending Dose/Proof of Concept Study of XTMAB-16 in Patients With Pulmonary Sarcoidosis With or Without Extrapulmonary Manifestations. A phase 1b/2 study of XTMAB-16 in patients with pulmonary sarcoidosis
• In September 2024:- Bristol-Myers Squibb- A Multicenter, Randomized, Double-blind, Placebo-controlled, Phase 3 Study to Evaluate the Efficacy, Safety, and Tolerability of BMS-986278 in Participants With Progressive Pulmonary Fibrosis. The purpose of this study is to evaluate the efficacy, safety, and tolerability of BMS-986278 in Participants with Progressive Pulmonary Fibrosis.
• DelveInsight’s Pulmonary Sarcoidosis pipeline report depicts a robust space with 10+ active players working to develop 10+ pipeline therapies for Pulmonary Sarcoidosis treatment.
• The leading Pulmonary Sarcoidosis Companies such as Novartis, aTyr Pharma, Relief Therapeutics, AI Therapeutics, SarcoMed USA, and others.
• Promising Pulmonary Sarcoidosis Therapies such as BMS-986278, Inhaled Treprostinil, Namilumab, and others

 

Stay ahead with the most recent pipeline outlook for Pulmonary Sarcoidosis. Get insights into clinical trials, emerging therapies, and leading companies with DelveInsight @ Pulmonary Sarcoidosis Treatment Drugs

 

Pulmonary Sarcoidosis Emerging Drugs

 

• CMK 389: Novartis

CMK 389 acts as inhibitors of Interleukin 18. It is being developed by Novartis for Pulmonary sarcoidosis and is currently in phase II stage of development.

 

• ATYR1923: aTyr Pharma

ATYR1923 is a potential first-in-class, disease modifying therapy for patients with severe inflammatory lung diseases with high unmet medical need. ATYR1923 works by selectively modulating Neuropilin-2 (NRP2) to downregulate the innate and adaptive immune responses in uncontrolled inflammatory disease states to resolve inflammation and prevent subsequent fibrosis. ATYR1923 is conducting a Phase 1b/2a clinical trial in pulmonary sarcoidosis, a major form of interstitial lung disease (ILD), a group of immune-mediated disorders that cause progressive fibrosis of the lung.

 

Explore groundbreaking therapies and clinical trials in the Pulmonary Sarcoidosis Pipeline. Access DelveInsight’s detailed report now! @ New Pulmonary Sarcoidosis Drugs

 

Pulmonary Sarcoidosis pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration

• Infusion
• Intradermal
• Intramuscular
• Intranasal
• Intravaginal
• Oral
• Parenteral
• Subcutaneous
• Topical
• Molecule Type

 

Pulmonary Sarcoidosis Products have been categorized under various Molecule types such as

• Vaccines
• Monoclonal Antibody
• Peptides
• Polymer
• Small molecule
• Product Type

 

Unveil the future of Pulmonary Sarcoidosis Treatment. Learn about new drugs, pipeline developments, and key companies with DelveInsight’s expert analysis @ Pulmonary Sarcoidosis Market Drivers and Barriers

 

Scope of the Pulmonary Sarcoidosis Pipeline Report

• Coverage- Global
• Pulmonary Sarcoidosis Companies- Novartis, aTyr Pharma, Relief Therapeutics, AI Therapeutics, SarcoMed USA, and others.
• Pulmonary Sarcoidosis Therapies- BMS-986278, Inhaled Treprostinil, Namilumab, and others.
• Pulmonary Sarcoidosis Therapeutic Assessment by Product Type: Mono, Combination, Mono/Combination
• Pulmonary Sarcoidosis Therapeutic Assessment by Clinical Stages: Discovery, Pre-clinical, Phase I, Phase II, Phase III

 

Get the latest on Pulmonary Sarcoidosis Therapies and clinical trials. Download DelveInsight’s in-depth pipeline report today! @ Pulmonary Sarcoidosis Companies, Key Products and Unmet Needs

 

Table of Content

1. Introduction
2. Executive Summary
3. Pulmonary Sarcoidosis: Overview
4. Pipeline Therapeutics
5. Therapeutic Assessment
6. Pulmonary Sarcoidosis– DelveInsight’s Analytical Perspective
7. In-depth Commercial Assessment
8. Pulmonary Sarcoidosis Collaboration Deals
9. Late Stage Products (Phase III)
10. Drug Name: Company Name
11. Drug profiles in the detailed report…..
12. Mid Stage Products (Phase II)
13. CMK389: Novartis
14. Drug profiles in the detailed report…..
15. Early Stage Products (Phase I/II)
16. ATYR1923: aTyr Pharma
17. Drug profiles in the detailed report…..
18. Early Stage Products (Phase I)
19. LAM–001: AI Therapeutics
20. Drug profiles in the detailed report…..
21. Inactive Products
22. Pulmonary Sarcoidosis Key Companies
23. Pulmonary Sarcoidosis Key Products
24. Pulmonary Sarcoidosis- Unmet Needs
25. Pulmonary Sarcoidosis- Market Drivers and Barriers
26. Pulmonary Sarcoidosis- Future Perspectives and Conclusion
27. Pulmonary Sarcoidosis Analyst Views
28. Pulmonary Sarcoidosis Key Companies
29. Appendix

 

About Us

DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Yash Bhardwaj
Email: Send Email
Phone: 9650213330
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/